Moderna’s RSV Vaccine Gets Positive Opinion from EU Advisory Panel
Moderna Inc.’s stock rose 1.1% early Friday, after the biotech said an advisory panel to the European Union’s medical regulator had adopted a positive opinion on its respiratory syncytial virus vaccine for adults aged 60 and older. The vaccine called mResvia has already been approved by the U.S. Food and Drug Administration, becoming Moderna’s second approved product after its COVID-19 vaccine, Spikevax. “mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a p